A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia; BMC Medical Genetics; Vol. 20
| Parent link: | BMC Medical Genetics Vol. 20.— 2019.— [47, 10 p.] |
|---|---|
| Körperschaft: | |
| Weitere Verfasser: | , , , , , , , , , , , , |
| Zusammenfassung: | Title screen Background: Hyperprolactinemia (HPRL) is a classical side effect of antipsychotic drugs primarily attributed to blockade of dopamine D2 receptors (DRD2s) on the membranes of lactotroph cells within the pituitary gland. Certain antipsychotic drugs, e.g. risperidone, are more likely to induce HPRL because of relative accumulation within the adenohypophysis. Nevertheless, due to competition for pituitary DRD2s by high dopamine levels may limit antipsychotic-induced HPRL. Moreover, the activity of prolactin-producing lactotrophs also depends on other hormones which are regulated by the extra-pituitary activity of dopamine receptors, dopamine transporters, enzymes of neurotransmitter metabolism and other factors. Polymorphic variants in the genes coding for these receptors and proteins can have functional significance and influence on the development of hyperprolactinemia. Methods: A set of 41 SNPs of genes for dopamine receptors DRD1, DRD2, DRD3, DRD4, the dopamine transporter SLC6A3 and dopamine catabolizing enzymes MAOA and MAOB was investigated in a population of 446 Caucasians (221 males/225 females) with a clinical diagnosis of schizophrenia (according to ICD-10: F20) with and without HPRL who were treated with classical and/or atypical antipsychotic drugs. Additive genetic model was tested and the analysis was carried out in the total group and in subgroup stratified by the use of risperidone/paliperidone. Results: One statistically significant association between polymorphic variant rs1799836 of MAOB gene and HPRL in men was found in the total group. Furthermore, the rs40184 and rs3863145 variants in SLC6A3 gene appeared to be associated with HPRL in the subgroup of patients using the risperidone/paliperidone, but not with HPRL induced by other antipsychotic drugs. |
| Sprache: | Englisch |
| Veröffentlicht: |
2019
|
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1186/s12881-019-0773-3 |
| Format: | Elektronisch Buchkapitel |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=664711 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 664711 | ||
| 005 | 20250121165301.0 | ||
| 035 | |a (RuTPU)RU\TPU\network\35895 | ||
| 035 | |a RU\TPU\network\34986 | ||
| 090 | |a 664711 | ||
| 100 | |a 20210514d2019 k||y0rusy50 ba | ||
| 101 | 0 | |a eng | |
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a i | |
| 182 | 0 | |a b | |
| 200 | 1 | |a A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia |f D. Z. Osmanova, M. B. Freydin, O. Yu. Fedorenko [et al.] | |
| 203 | |a Text |c electronic | ||
| 300 | |a Title screen | ||
| 320 | |a [References: 62 tit.] | ||
| 330 | |a Background: Hyperprolactinemia (HPRL) is a classical side effect of antipsychotic drugs primarily attributed to blockade of dopamine D2 receptors (DRD2s) on the membranes of lactotroph cells within the pituitary gland. Certain antipsychotic drugs, e.g. risperidone, are more likely to induce HPRL because of relative accumulation within the adenohypophysis. Nevertheless, due to competition for pituitary DRD2s by high dopamine levels may limit antipsychotic-induced HPRL. Moreover, the activity of prolactin-producing lactotrophs also depends on other hormones which are regulated by the extra-pituitary activity of dopamine receptors, dopamine transporters, enzymes of neurotransmitter metabolism and other factors. Polymorphic variants in the genes coding for these receptors and proteins can have functional significance and influence on the development of hyperprolactinemia. Methods: A set of 41 SNPs of genes for dopamine receptors DRD1, DRD2, DRD3, DRD4, the dopamine transporter SLC6A3 and dopamine catabolizing enzymes MAOA and MAOB was investigated in a population of 446 Caucasians (221 males/225 females) with a clinical diagnosis of schizophrenia (according to ICD-10: F20) with and without HPRL who were treated with classical and/or atypical antipsychotic drugs. Additive genetic model was tested and the analysis was carried out in the total group and in subgroup stratified by the use of risperidone/paliperidone. Results: One statistically significant association between polymorphic variant rs1799836 of MAOB gene and HPRL in men was found in the total group. Furthermore, the rs40184 and rs3863145 variants in SLC6A3 gene appeared to be associated with HPRL in the subgroup of patients using the risperidone/paliperidone, but not with HPRL induced by other antipsychotic drugs. | ||
| 461 | |t BMC Medical Genetics | ||
| 463 | |t Vol. 20 |v [47, 10 p.] |d 2019 | ||
| 610 | 1 | |a электронный ресурс | |
| 610 | 1 | |a труды учёных ТПУ | |
| 610 | 1 | |a dopamine receptors genes | |
| 610 | 1 | |a dopamine transporter SlC6A3 | |
| 610 | 1 | |a monoamine oxidase (MAO) | |
| 610 | 1 | |a antipsychotics | |
| 610 | 1 | |a hyperprolactinemia | |
| 610 | 1 | |a гены | |
| 610 | 1 | |a рецепторы | |
| 610 | 1 | |a гиперпролактинемия | |
| 610 | 1 | |a генетические исследования | |
| 610 | 1 | |a антипсихотические препараты | |
| 701 | 1 | |a Osmanova |b D. Z. |g Diana Zakirovna | |
| 701 | 1 | |a Freydin |b M. B. |g Maksim Borisovich | |
| 701 | 1 | |a Fedorenko |b O. Yu. |c specialist in the field of ecology and life safety |c Professor of Tomsk Polytechnic University, doctor of medical sciences |f 1973- |g Olga Yurievna |3 (RuTPU)RU\TPU\pers\33861 |9 17450 | |
| 701 | 1 | |a Pozhidaev |b I. V. |g Ivan Vyacheslavovich | |
| 701 | 1 | |a Boyko |b A. S. | |
| 701 | 1 | |a Vyalova |b N. M. |g Nataljya Mikhaylovna | |
| 701 | 1 | |a Tiguntsev |b V. V. |g Vladimir Vladimirovich | |
| 701 | 1 | |a Kornetova |b E. G. |g Elena Georgievna | |
| 701 | 1 | |a Loonen |b A. J. M. |g Anton | |
| 701 | 1 | |a Semke |b A. V. |g Arkady Valentinovich | |
| 701 | 1 | |a Wilffert |b B. |g Bob | |
| 701 | 1 | |a Bokhan |b N. A. |g Nikolay Aleksandrovich | |
| 701 | 1 | |a Ivanova |b S. A. |c specialist in the field of ecology and life safety |c Professor of Tomsk Polytechnic University, doctor of medical sciences |f 1964- |g Svetlana Aleksandrovna |3 (RuTPU)RU\TPU\pers\33859 | |
| 712 | 0 | 2 | |a Национальный исследовательский Томский политехнический университет |b Инженерная школа неразрушающего контроля и безопасности |b Отделение контроля и диагностики |3 (RuTPU)RU\TPU\col\23584 |
| 801 | 2 | |a RU |b 63413507 |c 20210514 |g RCR | |
| 856 | 4 | |u https://doi.org/10.1186/s12881-019-0773-3 | |
| 942 | |c CF | ||